ANI PHARMACEUTICALS INC (ANIP) Stock Fundamental Analysis
USA - NASDAQ:ANIP - US00182C1036 - Common Stock
90.88 USD
+0.65 (+0.72%)
Overall ANIP gets a fundamental rating of 5 out of 10. We evaluated ANIP against 192 industry peers in the Pharmaceuticals industry. ANIP has only an average score on both its financial health and profitability. An interesting combination arises when we look at growth and value: ANIP is growing strongly while it also seems undervalued.
1. Profitability
1.1 Basic Checks
ANIP had positive earnings in the past year.
ANIP had a positive operating cash flow in the past year.
ANIP had negative earnings in 4 of the past 5 years.
ANIP had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
ANIP has a better Return On Assets (-1.06%) than 78.13% of its industry peers.
With a decent Return On Equity value of -3.08%, ANIP is doing good in the industry, outperforming 78.65% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 1.63%, ANIP is in the better half of the industry, outperforming 79.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.06% | ||
| ROE | -3.08% | ||
| ROIC | 1.63% |
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Operating Margin value of 3.05%, ANIP is doing good in the industry, outperforming 79.69% of the companies in the same industry.
ANIP's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 61.06%, ANIP is in the better half of the industry, outperforming 69.79% of the companies in the same industry.
In the last couple of years the Gross Margin of ANIP has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.05% | ||
| PM (TTM) | N/A | ||
| GM | 61.06% |
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
2. Health
2.1 Basic Checks
ANIP has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ANIP has been increased compared to 1 year ago.
Compared to 5 years ago, ANIP has more shares outstanding
The debt/assets ratio for ANIP is higher compared to a year ago.
2.2 Solvency
ANIP has an Altman-Z score of 2.23. This is not the best score and indicates that ANIP is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.23, ANIP is in the better half of the industry, outperforming 65.63% of the companies in the same industry.
The Debt to FCF ratio of ANIP is 4.95, which is a neutral value as it means it would take ANIP, 4.95 years of fcf income to pay off all of its debts.
ANIP's Debt to FCF ratio of 4.95 is amongst the best of the industry. ANIP outperforms 83.85% of its industry peers.
ANIP has a Debt/Equity ratio of 1.32. This is a high value indicating a heavy dependency on external financing.
ANIP has a Debt to Equity ratio of 1.32. This is in the lower half of the industry: ANIP underperforms 76.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.32 | ||
| Debt/FCF | 4.95 | ||
| Altman-Z | 2.23 |
ROIC/WACC0.19
WACC8.68%
2.3 Liquidity
A Current Ratio of 2.54 indicates that ANIP has no problem at all paying its short term obligations.
The Current ratio of ANIP (2.54) is comparable to the rest of the industry.
A Quick Ratio of 1.96 indicates that ANIP should not have too much problems paying its short term obligations.
ANIP has a Quick ratio (1.96) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.54 | ||
| Quick Ratio | 1.96 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 43.78% over the past year.
ANIP shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 0.59% yearly.
ANIP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.50%.
The Revenue has been growing by 24.37% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)43.78%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%76.47%
Revenue 1Y (TTM)10.5%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%53.12%
3.2 Future
Based on estimates for the next years, ANIP will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.26% on average per year.
ANIP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.55% yearly.
EPS Next Y42.68%
EPS Next 2Y25.27%
EPS Next 3Y21.64%
EPS Next 5Y16.26%
Revenue Next Year40.72%
Revenue Next 2Y24.17%
Revenue Next 3Y19%
Revenue Next 5Y12.55%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 14.05, the valuation of ANIP can be described as correct.
Based on the Price/Earnings ratio, ANIP is valued cheaply inside the industry as 88.02% of the companies are valued more expensively.
ANIP is valuated rather cheaply when we compare the Price/Earnings ratio to 25.67, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 11.14, the valuation of ANIP can be described as very reasonable.
ANIP's Price/Forward Earnings ratio is rather cheap when compared to the industry. ANIP is cheaper than 85.94% of the companies in the same industry.
ANIP's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 31.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.05 | ||
| Fwd PE | 11.14 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ANIP is valued a bit cheaper than the industry average as 79.69% of the companies are valued more expensively.
85.42% of the companies in the same industry are more expensive than ANIP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.16 | ||
| EV/EBITDA | 22.41 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ANIP's earnings are expected to grow with 21.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.33
PEG (5Y)23.92
EPS Next 2Y25.27%
EPS Next 3Y21.64%
5. Dividend
5.1 Amount
No dividends for ANIP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ANIP (11/7/2025, 2:39:34 PM)
90.88
+0.65 (+0.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners93.3%
Inst Owner Change-0.13%
Ins Owners7.14%
Ins Owner Change-3.41%
Market Cap2.03B
Revenue(TTM)747.40M
Net Income(TTM)-14.22M
Analysts84.29
Price Target107.97 (18.81%)
Short Float %12.53%
Short Ratio6.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP-11.43%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.41%
Min EPS beat(2)20.55%
Max EPS beat(2)24.28%
EPS beat(4)4
Avg EPS beat(4)19.29%
Min EPS beat(4)11.36%
Max EPS beat(4)24.28%
EPS beat(8)8
Avg EPS beat(8)20.48%
EPS beat(12)12
Avg EPS beat(12)41.58%
EPS beat(16)13
Avg EPS beat(16)15.24%
Revenue beat(2)2
Avg Revenue beat(2)7.93%
Min Revenue beat(2)6.96%
Max Revenue beat(2)8.9%
Revenue beat(4)4
Avg Revenue beat(4)5.79%
Min Revenue beat(4)0.74%
Max Revenue beat(4)8.9%
Revenue beat(8)8
Avg Revenue beat(8)7%
Revenue beat(12)12
Avg Revenue beat(12)9.13%
Revenue beat(16)15
Avg Revenue beat(16)7.25%
PT rev (1m)6.31%
PT rev (3m)30.92%
EPS NQ rev (1m)2.33%
EPS NQ rev (3m)14.53%
EPS NY rev (1m)0.36%
EPS NY rev (3m)11.51%
Revenue NQ rev (1m)1.35%
Revenue NQ rev (3m)8.87%
Revenue NY rev (1m)0.34%
Revenue NY rev (3m)6.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.05 | ||
| Fwd PE | 11.14 | ||
| P/S | 2.71 | ||
| P/FCF | 16.16 | ||
| P/OCF | 14.57 | ||
| P/B | 4.39 | ||
| P/tB | N/A | ||
| EV/EBITDA | 22.41 |
EPS(TTM)6.47
EY7.12%
EPS(NY)8.16
Fwd EY8.98%
FCF(TTM)5.63
FCFY6.19%
OCF(TTM)6.24
OCFY6.87%
SpS33.52
BVpS20.7
TBVpS-5.35
PEG (NY)0.33
PEG (5Y)23.92
Graham Number54.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.06% | ||
| ROE | -3.08% | ||
| ROCE | 2.06% | ||
| ROIC | 1.63% | ||
| ROICexc | 2.04% | ||
| ROICexgc | 5.97% | ||
| OM | 3.05% | ||
| PM (TTM) | N/A | ||
| GM | 61.06% | ||
| FCFM | 16.78% |
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-44.22%
ROICexc growth 3YN/A
ROICexc growth 5Y-46.62%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
F-Score3
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.32 | ||
| Debt/FCF | 4.95 | ||
| Debt/EBITDA | 5.67 | ||
| Cap/Depr | 16.2% | ||
| Cap/Sales | 1.83% | ||
| Interest Coverage | 1.03 | ||
| Cash Conversion | 129.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.54 | ||
| Quick Ratio | 1.96 | ||
| Altman-Z | 2.23 |
F-Score3
WACC8.68%
ROIC/WACC0.19
Cap/Depr(3y)17.9%
Cap/Depr(5y)14.57%
Cap/Sales(3y)2.42%
Cap/Sales(5y)2.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.78%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%76.47%
EPS Next Y42.68%
EPS Next 2Y25.27%
EPS Next 3Y21.64%
EPS Next 5Y16.26%
Revenue 1Y (TTM)10.5%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%53.12%
Revenue Next Year40.72%
Revenue Next 2Y24.17%
Revenue Next 3Y19%
Revenue Next 5Y12.55%
EBIT growth 1Y-61.84%
EBIT growth 3YN/A
EBIT growth 5Y-34.31%
EBIT Next Year46.79%
EBIT Next 3Y23.35%
EBIT Next 5Y16.9%
FCF growth 1Y307.02%
FCF growth 3Y297.63%
FCF growth 5Y4.15%
OCF growth 1Y237.06%
OCF growth 3Y168.16%
OCF growth 5Y7.01%
ANI PHARMACEUTICALS INC / ANIP FAQ
What is the fundamental rating for ANIP stock?
ChartMill assigns a fundamental rating of 5 / 10 to ANIP.
What is the valuation status of ANI PHARMACEUTICALS INC (ANIP) stock?
ChartMill assigns a valuation rating of 8 / 10 to ANI PHARMACEUTICALS INC (ANIP). This can be considered as Undervalued.
Can you provide the profitability details for ANI PHARMACEUTICALS INC?
ANI PHARMACEUTICALS INC (ANIP) has a profitability rating of 4 / 10.
Can you provide the financial health for ANIP stock?
The financial health rating of ANI PHARMACEUTICALS INC (ANIP) is 4 / 10.
Can you provide the expected EPS growth for ANIP stock?
The Earnings per Share (EPS) of ANI PHARMACEUTICALS INC (ANIP) is expected to grow by 42.68% in the next year.